2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸 | 391211-97-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸
• 中文别名: 2-(2-氟-4-碘苯胺基)-3,4-二氟苯甲酸
• 英文名称: 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid
• 英文别名: PD-0315209；3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid；3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid
• CAS: 391211-97-5
• 化学式: C₁₃H₇F₃INO₂
• 分子量: 393.104
• InChiKey: REMYZOSCCVDLDL-UHFFFAOYSA-N

物化性质

• 熔点：
  189-191°C
• 沸点：
  370.1±42.0 °C(Predicted)
• 密度：
  1.939±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2922499990
• 危险标志：
  GHS07
• 危险性描述：
  H302,H413
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid
CAS number: 391211-97-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H7F3INO2
Molecular weight: 393.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸 在 4-二甲氨基吡啶 、 氯化铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 锌 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.2h， 生成 考比替尼
  参考文献：
  名称：

  一种卡比替尼的化学合成方法

  摘要：

  本发明属于化学合成领域，具体涉及一种卡比替尼的制备方法。该方法以2,3,4‑三氟苯甲酸苄酯为起始原料，通过取代反应、脱保护反应、酰胺化反应、催化加成反应等步骤得到卡比替尼。该方法原料价廉易得，工艺路线段，工反应过程易于操作，收率高，且环境友好，适合工业化大批量生产。

  公开号：

  CN106866624A
• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 20.0 ℃ 、413.69 kPa 条件下， 以98.8%的产率得到2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸
  参考文献：
  名称：

  一种卡比替尼的化学合成方法

  摘要：

  本发明属于化学合成领域，具体涉及一种卡比替尼的制备方法。该方法以2,3,4‑三氟苯甲酸苄酯为起始原料，通过取代反应、脱保护反应、酰胺化反应、催化加成反应等步骤得到卡比替尼。该方法原料价廉易得，工艺路线段，工反应过程易于操作，收率高，且环境友好，适合工业化大批量生产。

  公开号：

  CN106866624A
• 作为试剂：
  描述：

  2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸 、 (R)-o-((2,2-二甲基-1,3-二氧杂烷-4-基)甲基)羟胺 在 2-(2-氟-4-碘苯胺)-3,4-二氟苯甲酸 作用下， 以79.8的产率得到N-((R)-2,2-dimethyl-(1,3)dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
  参考文献：
  名称：

  Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids

  摘要：

  本发明涉及4-碘苯胺苯羟肟酸衍生物的氧化酯、制药组合物及其使用方法。本发明还涉及氧化酯的晶体形式的4-碘苯胺苯羟肟酸衍生物、制药组合物及其使用方法。

  公开号：

  US06960614B2

文献信息

• Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy
  作者：Xiaoxiao Li、Jianjun Hou、Chao Wang、Xinjie Liu、Hongyan He、Ping Xu、Zhenjun Yang、Zili Chen、Yun Wu、Lihe Zhang

  DOI：10.3390/molecules181113957

  日期：——

  Two novel series of RGD-MEKI conjugates derived from a MEK1/2 kinase inhibitor—PD0325901—have been developed for integrin receptor mediated anticancer therapy. The first series, alkoxylamine analog RGD-MEKI conjugates 9a–g showed anti-proliferation activity in melanoma A375 cells by the same mechanism as that of PD0325901. PEGylation increased the IC50 value of 9f three-fold in the A375 assay, and the multi-cRGD peptide cargo significantly improved the receptor specific anti-proliferation activity of 9g in integrin-overexpressing U87 cells. In the second series, RGD-PD0325901 13 exhibited significantly increased antitumor properties compared to the alkoxylamine analogs by both inhibition of the ERK pathway activity and DNA replication of the cancer cells. Furthermore, 13 displayed more potent anti-proliferation activity in the U87 assay than PD0325901 in a dose-dependent manner. All these data demonstrate that RGD-MEKI conjugates with an ester bond linkage enhanced anticancer efficacy with improved targeting capability toward integrin-overexpressing tumor cells.

  两种源于MEK1/2激酶抑制剂PD0325901的新型RGD-MEKI偶联物系列已被开发用于整合素受体介导的癌症治疗。第一系列，烷氧基胺类似物RGD-MEKI偶联物9a-g通过与PD0325901相同的机制在黑色素瘤A375细胞中显示出抗增殖活性。PEGylation使9f在A375测定中的IC50值增加了三倍，而多cRGD肽负载则显著提高了9g在整合素高表达的U87细胞中的受体特异性抗增殖活性。在第二系列中，RGD-PD0325901 13相比烷氧基胺类似物，通过抑制ERK通路活性和癌细胞的DNA复制，显示出显著增强的抗肿瘤特性。此外，13在U87测定中比PD0325901显示出更强的抗增殖活性，且呈剂量依赖性。所有这些数据表明，带有酯键连接的RGD-MEKI偶联物提高了对整合素高表达肿瘤细胞的靶向能力，从而增强了抗癌疗效。
• 具有肿瘤导向性治疗作用的多肽-药物缀合物 及其应用
  申请人：北京大学

  公开号：CN104248770B

  公开（公告）日：2017-06-13

  本发明涉及提供具有肿瘤导向性治疗作用的多肽‑药物缀合物，多肽‑药物缀合物的制备方法及其应用。本发明多肽‑药物缀合物可以特异性的将PD0325901类似物输送到整合素αvβ3过量表达的癌细胞内，进而起到对肿瘤导向性治疗的作用。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
  申请人：——

  公开号：US20040006245A1

  公开（公告）日：2004-01-08

  The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及氧化酯化的4-取代苯胺基苯基羟肟酸衍生物，以及其药物组合物和使用方法。
• Design and Synthesis of Minimalist Terminal Alkyne-Containing Diazirine Photo-Crosslinkers and Their Incorporation into Kinase Inhibitors for Cell- and Tissue-Based Proteome Profiling
  作者：Zhengqiu Li、Piliang Hao、Lin Li、Chelsea Y. J. Tan、Xiamin Cheng、Grace Y. J. Chen、Siu Kwan Sze、Han-Ming Shen、Shao Q. Yao

  DOI：10.1002/anie.201300683

  日期：2013.8.12

  “clickable” photo‐crosslinker (see scheme) was incorporated with numerous small‐molecule kinase inhibitors. The resulting probes were used for both in vitro (cell lysates) and in situ (live cells) proteome profiling, for large‐scale identification of their potential cellular kinase targets and shows improved outcomes over previous probes.

  少即是多：极简的“可点击”光交联剂（参见方案）与许多小分子激酶抑制剂结合在一起。所得的探针可用于体外（细胞裂解物）和原位（活细胞）蛋白质组分析，以大规模鉴定其潜在的细胞激酶靶标，并显示出比以前的探针更好的结果。